GAMMA Investing LLC Has $12.54 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

GAMMA Investing LLC grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 12,517.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,442 shares of the medical equipment provider's stock after acquiring an additional 127,424 shares during the quarter. GAMMA Investing LLC owned about 0.19% of Lantheus worth $12,536,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Moody National Bank Trust Division boosted its holdings in shares of Lantheus by 1.0% during the first quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock worth $1,455,000 after purchasing an additional 141 shares during the last quarter. Wellington Management Group LLP purchased a new position in Lantheus during the fourth quarter worth about $20,022,000. Wealth Enhancement Advisory Services LLC boosted its stake in Lantheus by 16.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,184 shares of the medical equipment provider's stock worth $374,000 after buying an additional 576 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Lantheus in the 4th quarter valued at about $13,081,000. Finally, Mackenzie Financial Corp increased its stake in shares of Lantheus by 4,907.1% during the 4th quarter. Mackenzie Financial Corp now owns 217,056 shares of the medical equipment provider's stock valued at $19,418,000 after acquiring an additional 212,721 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on LNTH. Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $132.67.

Lantheus Stock Performance

Shares of LNTH stock traded down $2.80 during trading hours on Tuesday, hitting $80.42. 1,190,596 shares of the company were exchanged, compared to its average volume of 1,005,876. The business's 50-day simple moving average is $89.64 and its two-hundred day simple moving average is $91.61. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The stock has a market capitalization of $5.56 billion, a price-to-earnings ratio of 13.38 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.69 EPS. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director now owns 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,068 shares of company stock worth $3,008,051 over the last three months. Corporate insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.